1. CCL Products India:

Axis Direct maintains its ‘Buy’ rating on this coffee producer, with a target price of Rs 1,140, an upside of 10.1%. The company delivered a strong Q2FY26 – its revenue surged 52.6% YoY to Rs 1,127 crore, driven by higher volumes across both business-to-business (B2B) and business-to-customer (B2C) segments. Analyst Suhanee Shome believes strong volume growth, strategic capacity expansion, and portfolio diversification into FMCG products will fuel long-term growth.

The company gained market share across channels and geographies, driving growth in its B2B and B2C segments. Management aims to diversify beyond coffee, leveraging its 1.3-1.4 lakh outlet distribution network to launch new FMCG categories like iced tea and snacks. The analyst notes CCL Products is consolidating its position as a leading player in modern trade and e-commerce, holding double-digit market share pan-India and ranking among the top players in Andhra Pradesh and Telangana. 

Shome expects resilient EBITDA growth, despite cost headwinds, and debt moderation efforts to drive net profit growth. She projects CCL Products will achieve revenue and net profit CAGRs of 23% and 31.4%, respectively, from FY26-28.

2. Narayana Hrudayalaya (NARH): 

Prabhudas Lilladher retains its ‘Buy’ rating on this hospital chain, with a target price of Rs 2,000, a 13.7% upside. Analysts Param Desai and Sanketa Kohale note the company trades at a discount to peers due to its greater international exposure and fewer planned Indian bed additions over the next two years.

NARH signed an agreement to acquire 100% of UK-based Practice Plus Group Hospitals (PPG Hospitals) for GBP 183 million (approximately Rs 2,100 crore). This marks its second major international expansion, following the Cayman Islands. The PPG Hospitals operation includes seven hospitals, three surgical centres and two urgent treatment centres, with a total capacity of around 330 beds. Analysts believe the company’s international business will achieve strong margin growth over the next three years as both Cayman's new unit and PPG Hospitals have the potential to scale up.

Desai and Kohale highlight the company's plan to drive growth in the Indian market through debottlenecking, refurbishment, improved pricing for government scheme patients, and optimising its bed mix over the next three years. They project NARH will achieve a 13.6% revenue CAGR, 17% EBITDA CAGR, and 19.6% net profit CAGR from FY26-28.

3. DLF: 

ICICI Direct retains its ‘Buy’ rating on this realty company with a target price of Rs 1,000, an upside of 30.7%. DLF's Q2FY26 pre-sales jumped 6.3 times YoY to Rs 4,332 crore. A strong response to its first Mumbai project, The Westpark, and continued demand for its luxury project Camellias drove this surge. However, revenue declined 17% because of lower booking recognition. Analysts Ronald Siyoni and Dilip Pandey note DLF achieved Rs 15,750 crore in pre-sales during H1FY26, positioning the company well to meet its annual target.

Management maintains its FY26 pre-sales guidance of Rs 20,000–22,000 crore and expects collections to improve in H2. It plans Rs 5,000 crore in capital expenditure annually for FY26 and FY27 for rental asset additions and new project launches. DLF's 49 million square feet of commercial rental assets operate at 94% occupancy. The company expects to commission an additional 2.7 million square feet in FY26. 

Siyoni and Pandey believe DLF is well-placed to sustain growth, given its strong launch pipeline worth Rs 60,200 crore. Upcoming launches include residential projects in Goa and Panchkula, along with new phases of Privana, Westpark, and Hamilton in Gurugram and Mumbai. They expect stable sales momentum, robust cash flows, and steady rental income to drive earnings.

4. UPL: 

Anand Rathi upgrades this agrochemicals company to a ‘Buy’ call with a target price of Rs 820, an upside of 9%. UPL posted strong Q2FY26 results, with revenue growing 9.5% YoY, driven by improvements in the Latin American, Indian and North American markets. The company reported a net profit of Rs 553 crore, a turnaround from a Rs 443 crore net loss in Q2FY25, supported by a rich product mix and lower inventory costs. Analyst Himanshu Binani believes a focus on differentiated solutions and new product launches will drive growth and improve margins.

The analyst notes that robust sales volumes of key molecules like Metribuzin, Metolachlor, and Glufosinate in the US market supported North America's 63% YoY growth. Management maintains its 4-8% revenue growth guidance for FY26. It also increased its EBITDA guidance to 12-16% from 10-14%, focusing on introducing higher-margin products. UPL expects H2FY26 improvement from better weather visibility, higher Rabi planting, and strong demand recovery. 

Binani adds that ongoing capacity expansion in sustainable solutions and biosciences, alongside management's focus on preventing overstocking, will support medium-term growth. He projects UPL will achieve a revenue CAGR of 7.3% and a net profit CAGR of 67.5% over FY26-28.

5. Sun Pharmaceutical Industries:

Motilal Oswal reiterates its ‘Buy’ rating on this pharma company with a target price of Rs 1,960, an upside of 14.2%. Sun Pharma's net profit grew 2.6% YoY to Rs 3,118 crore in Q2FY26, boosted by lower material costs. Revenue increased 8.9%, as strong demand in India and emerging markets drove growth.

Management highlights strong global momentum in its innovative medicines business. Key products like Ilumya (for psoriasis) and Odomzo (for skin cancer) performed well. Sun Pharma plans to launch Unloxcyt (for certain cancers) in the US and file for a new psoriatic arthritis indication for Ilumya in H2FY26. The company spent Rs 780 crore on R&D (5.4% of sales), allocating 38% to innovative projects in Q2. It expects R&D costs to stay at the lower end of its 6-8% guidance for FY26. 

Analysts Tushar Manudhane and Eshita Jain believe Sun Pharma is well-placed to expand its branded and specialty therapies globally. They expect steady growth in India, supported by new product launches and a stronger presence in chronic therapies. The specialty portfolio, including Ilumya, Cequa (for dry eye disease), and Odomzo, is seen as the main driver of long-term growth, with an estimated 11% CAGR.

Note: These recommendations are from various analysts and are not recommendations by Trendlyne.

(You can find all analyst picks here)